Naturalistic, retrospective comparison between second-generation antipsychotics and depot neuroleptics in patients affected by schizophrenia

Journal of Clinical Psychiatry

Volumn 66, Issue 11, 2005, Pages 1423-1431

  Marchiaro, Livio ^a   Rocca, Paola ^a   LeNoci, Ferdinando ^a   Longo, Pierpaolo ^a   Montemagni, Cristiana ^a   Rigazzi, Cristiana ^a   Bogetto, Filippo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOTIAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; AUTOMUTILATION; CLINICAL EXAMINATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG FORMULATION; EXTRAPYRAMIDAL SYNDROME; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; OUTPATIENT; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 28844492199     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n1113     Document Type: Article

References (49)

1. Lehman AF, Lieberman JA, Dixon LB, et al. Practice Guideline for the Treatment of Patients With Schizophrenia, Second Edition. Am J Psychiatry 2004;161(suppl 2):1-56
2. Marder SR. Overview of partial compliance. J Clin Psychiatry 2003;64(suppl 16):3-9
3. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003;64:1308-1315
4. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995:21:419-429
5. Davis JM, Kane JM, Marder SR, et al. Dose response of prophylactic antipsychotics. J Clin Psychiatry 1993;54(3, suppl):24-30
6. Johnson DAW, Pasterski JM, Ludlow JM, et al. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 1983;67:339-352
7. Pandarakalam JP. Atypical and conventional depot medications. Hosp Med 2003:64:658-663
8. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998;8:55-66
9. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003;64(suppl 16):14-17
10. Adams CE, Fenton MKP, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001:179:290-299
11. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999:35:51-68
12. Meltzer HY. Outcome in schizophrenia: beyond symptom reduction. J Clin Psychiatry 1999:60(suppl 3):3-7
13. Guthrie SK. Clinical issues associated with maintenance treatment of patients with schizophrenia. Am J Health Syst Pharm 2002;59(suppl 5):19-24
14. Meltzer HY. Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. Curr Psychiatry Rep 2002;4:279-283
15. Noordsy DL, Green AI. Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Curr Psychiatry Rep 2003;5:340-346
16. Siris SG. Depression in schizophrenia: perspective in the era of "atypical" antipsychotic agents. Am J Psychiatry 2000;157:1379-1389
17. Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002:16:473-484
18. Davis JM, Chen N. Choice of maintenance medication for schizophrenia. J Clin Psychiatry 2003;64(suppl 16):24-33
19. Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004;18:877-893
20. Conley RR, Kelly DL, Love RC, et al. Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry 2003;15:23-31
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
22. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impression (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997;73:159-171
23. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
24. Green MF. What are the consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-330
25. Schiller MJ, Shumway M, Hargreaves WA. Treatment costs and patient outcomes with use of risperidone in a public mental health setting. Psychiatr Serv 1999;50:228-232
26. Doering S, Muller E, Kopcke W, et al. Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Bull 1998;24:87-98
27. Gaebel W. Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs. Int Clin Psychopharmacol 1997;12(suppl 1):37-42
28. Hogarty GE, Ulrich RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 1998;32:243-250
29. Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. Arch Gen Psychiatry 1997;54:453-463
30. Moore DB, Kelly DL, Sherr JD, et al. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am J Health Syst Pharm 1998;55(suppl 4):17-19
31. Tran PV, Dellva MA, Tollefson GD, et al. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998;172:499-505
32. Conley RR, Love RC, Kelly DL, et al. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 1999;156:863-868
33. Essock SM, Hargreaves WA, Covell NH, et al. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996;32:683-697
34. Hogarty GE. Prevention of relapse in chronic schizophrenic patients. J Clin Psychiatry 1993;54(3, suppl):18-23
35. Olfson M, Mechanic D, Boyer CA, et al. Assessing clinical predictions of early rehospitalization in schizophrenia. J Nerv Ment Dis 1999;187:721-729
36. Palmer DD, Henter ID, Wyatt RJ. Do antipsychotics medications decrease the risk of suicide in patients with schizophrenia? J Clin Psychiatry 1999;60(suppl 2):100-103
37. Wagstaff A, Perry C. Clozapine: in prevention of suicide in patients with schizophrenia or schizoaffective disorder. CNS Drugs 2003;17:273-280
38. Coley KC, Carter CS, DaPos SV, et al. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. J Clin Psychiatry 1999;60:850-856
39. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004;30:193-217
40. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544
41. Schooler NR. Maintenance medication for schizophrenia: strategies for dose reduction. Schizophr Bull 1991;17:311-324
42. Tran PV, Dellva MA, Tollefson GD, et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997;58:205-211
43. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003;28:995-1003
44. Inada T, Yagi G, Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res 2002;57:227-238
45. Emsley RA, Buckley P, Jones AM, et al. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol 2003;17:210-215
46. Gilbody S, Wahlbeck K, Adams C. Randomized controlled trials in schizophrenia: a critical perspective on the literature. Acta Psychiatr Scand 2002;105:243-251
47. Collaborative Working Group on Clinical Trial Evaluations. Clinical development of atypical antipsychotics: research design and evaluation. J Clin Psychiatry 1998;59(suppl 12):10-16
48. Dickson RA, Dalby JT, Addington D, et al. Hospital days in risperidone-treated patients. Can J Psychiatry 1999;44:909-913
49. Haro JM, Edgell ET, Jones PB, et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003;107:222-232